PTAB Ruling on Amgen’s Opdivo Challenge Highlights Evolving Patent Policy in Biopharma Industry
The Patent Trial and Appeal Board (PTAB) has recently concluded Amgen Inc.’s challenge to a now-disclaimed patent covering Bristol-Myers Squibb Co.’s cancer drug Opdivo and denied Bristol-Myers’ request to pursue a replacement patent. This decision underscores the PTAB’s stance against what it perceives as strategic maneuvers to extend patent protection. In July 2025, Acting Director…